TCF-001 TRACK: Target Rare Cancer Knowledge


Driving precision medicine in rare cancers.

Since being founded in 2009 by a patient facing cholangiocarcinoma, TargetCancer Foundation (TCF) has stood at the intersection of rare cancer patients, advocates, researchers, and clinicians. TCF is expanding its impact through TCF-001 TRACK, a prospective clinical trial seeking to enroll 400 patients with rare cancers or cancer of unknown primary.


In partnership with

TargetCancer Foundation would like to thank our research collaborator Foundation Medicine for their commitment and leadership in TRACK.

With gratitude for our supporters who share our passion for rare cancers and precision medicine. Contact us to learn more about how to partner on TRACK and future studies.

We’re partnering with leading researchers to make a real impact
Learn More